5 Biotech Stocks to Buy Now According to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital

4. Instil Bio, Inc. (NASDAQ:TIL)

Akkaraju and Dybbs’ Stake Value: $41,449,000
Percentage of Srini Akkaraju and Michael Dybbs’ 13F Portfolio: 5.11%
Number of Hedge Fund Holders: 14

Instil Bio, Inc. (NASDAQ:TIL) is a clinical-stage biopharmaceutical firm that develops treatments for cancer patients. The company was founded in 2018 and is placed fourth on the list of 15 biotech stocks to buy now according to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Instil Bio, Inc. (NASDAQ:TIL) shares have returned 6.48% to investors during the course of the past 12 months.

On August 12, Instil Bio, Inc. (NASDAQ:TIL) announced earnings for the second quarter of 2021. It reported earnings per share of –$0.27, missing the consensus by $0.06. Baird analyst Jack Allen initiated coverage of Instil Bio, Inc. (NASDAQ:TIL) with an “Outperform” rating and gave a price target of $34.

The hedge fund managed by Srini Akkaraju and Michael Dybbs currently holds 2.15 million shares of Instil Bio, Inc. (NASDAQ:TIL) that amount to $41.45 million after increasing its stakes by 39% in the second quarter of 2021. Instil Bio, Inc. (NASDAQ:TIL) occupies 5.11% of Samsara BioCapital’s total portfolio. In addition, Albert Cha and Frank Kung’s Vivo Capital is a leading shareholder in Adobe Inc. (NASDAQ: ADBE), with 12.49 million shares worth $241.25 million.